Cortexin vs Semax.

Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. It contains a mixture of short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements, and is supplied as a lyophilized powder reconstituted for intramuscular injection. Developed and marketed primarily in Russia by GEROPHARM, it is positioned as a neurotrophic and neuroprotective agent. It is used clinically within Russia and several neighboring countries for a range of neurological conditions.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment of adrenocorticotropic hormone joined to a C-terminal Pro-Gly-Pro tripeptide. It was developed in the late 1980s/early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and is first described in the scientific literature around 1991. The Pro-Gly-Pro extension stabilizes the otherwise rapidly degraded ACTH fragment without retaining ACTH's hormonal (corticosteroid-releasing) activity, making Semax a "neuropeptide" rather than a hormone.

Like other brain-tissue peptide preparations, Cortexin is a complex mixture, so its activity is attributed to the combined effect of many peptide-protein interactions rather than a single molecular target. Proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems such as GABA and dopamine. Its low-molecular-weight peptides are claimed to cross the blood-brain barrier. These mechanisms are largely inferred from preclinical models.

Semax is structurally derived from ACTH(4-10) but lacks the melanocortin-receptor-driven hormonal effects of full-length ACTH, so it does not stimulate cortisol release. Mechanistic (largely rodent and in vitro) work indicates it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, and modulates expression of NGF and other neurotrophic and immune-response genes, which is proposed to support neuronal survival and synaptic plasticity. A separate biochemical mechanism is inhibition of enkephalin-degrading enzymes in human serum (reported IC50 ~10 µM), which may prolong the activity of endogenous regulatory peptides. The relative contribution of each pathway to any observed clinical effect remains unsettled; Wikipedia and reviews note the precise mechanism of action is not definitively established.

The evidence base for Cortexin comes predominantly from Russian-language studies and preclinical models, with limited independent Western validation. A recent preclinical study (Kurkin et al., Biomedicines 2025) reported neurotropic effects in rat models of toxic and traumatic developmental delay. Clinical use is widespread in Russia across pediatric neurology, stroke rehabilitation and cognitive disorders, but large, blinded, international randomized trials indexed in mainstream databases are scarce. As a result, Cortexin has not been subjected to the RCT and Cochrane-level scrutiny applied to Cerebrolysin. Its efficacy claims should therefore be read with caution. The human literature is dominated by multicenter observational programs rather than randomized comparisons: the CORNELia program in chronic cerebrovascular disease with cognitive impairment and the CORTEX program in post-COVID neurological complaints are both described as observational, meaning they lack a concurrent randomized control arm, blinding, and placebo control, so improvement over time cannot be separated from natural recovery, regression to the mean or expectation effects. Comparative studies do exist within the same national literature, for example a comparison with another peptide preparation in the early recovery period after ischaemic stroke, but these are typically single-country, modest in size and published in one journal, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, closely associated with the domestic market for the drug. Preclinical support includes rodent work on antioxidant effects in chronic cerebrovascular insufficiency and a cell-culture study reporting protection of cultured rat sensory neurons from high-glucose injury. Nearly all of this literature originates in the country where the product is registered and marketed, and the manufacturer's involvement in the observational programs is a relevant consideration. What is missing is specific: no independent multinational randomized trial, no Cochrane or comparable systematic review, no published characterization of which peptides in the extract are active, and no external regulatory assessment of the manufacturing and potency standards. Cortexin sits alongside thymalin, vilon and epitalon in resting on single-country literature, while Cerebrolysin, despite its own unresolved questions, has at least been tested in independently reviewed randomized trials.

Human evidence comes almost entirely from Russian clinical research and is modest in scale. A representative controlled study by Gusev, Martynov and colleagues (Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983) in 110 ischemic-stroke patients reported that semax plus early rehabilitation raised plasma BDNF and improved motor recovery and functional independence (Barthel index). The strongest mechanistic data, BDNF/TrkB upregulation (Brain Research, 2006; PMID 16996037) and neuroprotection and immune-gene regulation in rat ischemia (Mol Genet Genomics, 2017; PMID 28255762), are preclinical (rat/in vitro). Proposed uses such as ADHD or cognitive enhancement rest largely on hypothesis papers (e.g., Med Hypotheses, 2007; PMID 16996699) rather than rigorous trials. Crucially, no large, independent, randomized, double-blind Western trials have replicated the Russian findings, so the human cognitive- and stroke-benefit claims should be regarded as preliminary.

Cortexin is generally described in its clinical literature as well tolerated when given intramuscularly, with hypersensitivity and allergic reactions being the main labeled concern. As a parenteral bovine-derived biological, theoretical risks include allergic reactions and injection-site effects, and the same category concerns apply that attach to any animal-tissue extract given by injection: immunogenicity on repeated courses, dependence on the source herd and purification process for freedom from adventitious agents, and the practical difficulty of proving batch equivalence for a mixture whose active constituents are not defined. Independent long-term safety data from outside its region of use are limited, and the observational design of most human reports means adverse events were collected without a comparator, so background rates cannot be separated from drug-related events. Use in children, which is common in the Russian pediatric neurology setting, has not been evaluated in independently reviewed controlled trials, and pediatric exposure is precisely the situation where an external safety assessment would ordinarily be required. Product acquired outside licensed pharmacy channels carries additional contamination and counterfeit risk, since injectables demand verified sterility and endotoxin control that unregulated supply cannot demonstrate. A trial-grade safety evaluation would include prospective adverse-event capture against a control arm, hypersensitivity monitoring, hepatic and renal laboratory follow-up, and anti-drug antibody testing on repeat courses. It is a prescription clinical product, not a dietary supplement.

Russian clinical reports and the intranasal route describe generally good tolerability, with mild nasal/local irritation the most commonly noted complaint; however, these data come from small studies without the long-term, independent safety surveillance expected for Western drug approval. There is no robust characterization of long-term safety, drug interactions, effects in pregnancy, or risks from non-pharmaceutical "research-use" material sold online, which may vary in purity and sterility. Because much of the mechanistic profile (BDNF/neurotrophin modulation, peptidase inhibition) is extrapolated from animal models, downstream effects of chronic human use are essentially unstudied. Product sold by online vendors is not manufactured to pharmaceutical standards and its identity and contaminants are not guaranteed.

Cortexin is not FDA-approved and is not marketed in the United States or the European Union. It is a registered prescription medicine in Russia and several post-Soviet states. This summary is educational and includes no dosing information.

Semax is approved as a prescription drug in Russia (and appears on Russia's List of Vital and Essential Drugs) for indications including ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved and is unscheduled in the United States, where it is sold by online vendors as a research/non-pharmaceutical product; it is not approved or marketed in most countries outside Russia.